We have previously suggested that colorectal liver metastases might produce 'toxins' that reduce both quality of life (QoL) and survival. In this study we assessed whether QoL in patients with such metastases was related to immune activation, as determined by increased serum levels of interleukin 6 (1L6), soluble tumour necrosis factor receptor 1 (sTNFrl), soluble interleukin 2 receptor alpha (slL2ra) or the interferon-y marker neopterin.
INTRODUCTION
We have previously reported that measurement of quality of life (QoL) in patients with colorectal liver metastases was a stronger predictor of survival than more conventional disease-related variables such as liver metastasis volume and serum carcinoembryonic antigen (CEA) and alkaline phosphatase levels1. To explain the finding that some patients with smaller tumours may have greater QoL deterioration and shorter survival than other patients with larger tumours, we suggested that colorectal liver metastases might produce, in varying amounts, 'toxins' that reduce both QoL and survival.
Depression and fatigue can be produced by administration of interleukin 22 or interferon3, and have also been reported in association with increased serum levels of the soluble portion of the interleukin 2 receptor alpha chain (sIL2rax) and endogenous interleukin 6 (IL6)4. Serum sIL2ra, IL6, and tumour necrosis factor receptor I (sTNFrl) levels are known to be raised in patients with advanced colorectal cancer5'6, and we wondered whether increased immune activation could cause these patients to become depressed. Departments We assessed whether QoL in a consecutive series of patients with colorectal liver metastases correlated with increases in serum levels of the cytokine IL6, the soluble cytokine receptors sTNFrl and sIL2ra, or the interferon y marker neopterin which is released by interferon-y from monocytes7.
MATERIALS AND METHODS

Patients
All patients studied had biopsy-confirmed colorectal liver metastases with no evidence of extrahepatic disease on abdominal computed tomographic (CT) scan and chest radiograph, and were treated with either continuous infusion systemic fluorouracil (450 mg/m2/day for 7 days/month) combined with folinic acid (30mg/m2/day for 7 days/month) or hepatic arterial floxuridine (0.2 mg/ kg bodyweight/day for 14 days/month). 3 patients also received systemic steroids for symptom control.
Variables measured
All patients completed the following QoL questionnaires:
Rotterdam Symptom Checklist (RSC)8, Hospital Anxiety and Depression scale (HAD)9, and the Sickness Impact Profile (SIP)10 at the time of blood sampling for immune products (before chemotherapy). Liver metastasis volume was measured by CT scan as previously describedl 1. Before patients began chemotherapy, peripheral venous blood was taken for estimation of serum alkaline phosphatase and CEA, and for measurement of serum IL6, sTNFrl, sIL2rax and neopterin by enzyme linked immunosorbent assays12 supplied by R and D Systems Europe Ltd, Abingdon, UK (IL6, sTNFrl, sIL2ra) and ICN Flow, Oxfordshire, UK (neopterin). Normal serum values reported by the suppliers were: IL6, median 1.62 ng/L (range 0.38-10.1), sTNFrl, 1198 ng/L (749-1966), sIL2ra, 1346ng/L (676-2132), neopterin < 10 nmol/L. The upper value in each range was taken as the upper limit of normal. The sIL2ra assay coefficients of variation13 were <6.1% (intra-assay) and <7.2% (inter-assay), and those for other assays were within a similar range.
Statistical analysis
Survival was measured in days from the date of blood sampling. Spearman correlations14, stepwise multiple regression analysis15, survival analysis with covariates (Cox's proportional hazards model)16 and logrank survival curve comparisons17'18 were used for statistical analysis as indicated. Survival was dichotomized as more or less than I year for correlations with HAD scale depression score because it was close to the median survival of the study group. Tumour volume and serum levels were not normally distributed and natural logarithms were used to ensure normality before the model was fitted in regression and covariate analyses, since normal variable distribution is an assumption of these methods. Similarly, .the natural logarithm of survival was used as an independent variable in stepwise multiple regression analysis when depression score was the dependent variable. Survival to the limit of follow-up in survivors is not distinguished from survival to death in regression analysis. However, there were no significant differences when analyses were run comparing data on patients who had died with those in all patients using the logarithm of survival to that date. Therefore, the regression analyses included survival in patients still alive at Table 2 Stepwise regression analysis using HAD (Hospital Anxiety and Depression) scale depression score as the dependent variable, and including both survival and tumour volume as independent variable (P value indicates probability that the variable included explains the variability in depression score)
Step 0
Step 1 See Table 1 for key to abbreviations completion of follow-up. Multivariate analyses assessing whether serum immune product levels contributed to variability in QoL scores (Tables 1 and 2 ) used both natural logarithms of continuous and binary transformed (elevated/ not elevated above upper limit of normal) immune product levels. As five correlations were performed between serum sIL2ra and QoL instruments, which would be correlated, a 1% level for statistical significance was stipulated in these analyses to reduce the risk of a type I errorI9.
The study was approved by the Chelsea and Westminster Hospital Research Ethics committee. RESULTS 
patients (median age 55 years, interquartile range [iqr]
50-66) with colorectal liver metastases (median tumour volume 420 mL, iqr 57-1142) were studied. Karnofsky score at the time of immune product measurement was 100 (13 patients), 90 (29 patients), or 80 (1 patient). The median number of treatment courses was 6 (iqr 4-10.75) for systemic and 7 (iqr 3-13) for hepatic arterial chemotherapy patients. 4 patients (all regional chemotherapy) showed a >50% reduction in liver metastasis volume (partial response) following chemotherapy. Overall patient survival from time of immune product sampling was a median of 308 days (iqr 170-666), median follow-up was 20 months with follow-up. 12 patients remaining alive by the end of
Pattern of immune product elevation
The levels of serum immune products detected before chemotherapy were IL6, median 6.2 ng/L (range 0-180.6); sTNFrl, 1922ng/L (1004.7-9031.9); sIL2ra, 1099ng/L (471.6-4541.2); neopterin 9.4mol/L (4.2-351). Serum immune product levels were not significantly correlated with each other, and their elevation above the previously defined upper normal limit did not invariably coincide in the same patients (Figure 1 ). Immune product levels did not differ between patients subsequently treated with systemic compared with hepatic arterial chemotherapy (Mann-Whitney U test).
Immune products and tumour volume There were positive correlations (Spearman) between pretreatment liver metastasis volume and pretreatment sIL2ra (r=0.55, P=0.0009) and IL6 (r=0.47, P=0.005), but not sTNFrl (r=0.3, P=0.09) or neopterin (r=0.28, P= 0.13) levels.
Immune products and survival
Survival (Figure 2 ) in patients with a pretreatment serum sIL2ra level of greater than the upper normal limit sIL2ra, shorter (logrank test, P=0.001) than in patients with lower levels (583 days). Similarly, survival was shorter (P =0.004) where the serum sTNFrl was >1966 (244 days) than in those with <1966ng/L (581 days), and where serum IL6 (P=0.01) was >10.1 (216 days) compared with <10.1 ng/ L (506 days). Significant survival differences where serum neopterin level was greater or less than 10nmol/L were not detected. Survival analysis with covariates (Table 1) comparing pretreatment serum immune product levels, tumour volume, serum alkaline phosphatase and CEA, and quality of life scores (RSC, HAD scale and SIP) selected serum sL2rac as a significant independent survival predictor.
Immune products and QoL There were positive correlations (Spearman) between serum sIL2ra and HAD scale depression (r=0.66, P<0.0001), RSC physical (r=0.46. P=0.01), and SIP (r=0.47, P=0.009) scores but not HAD scale anxiety score (r=-0.011, P=0.96). Significant correlations between 0.8-. L i.61 oe_slL2ra'2132 ng/1 0.i + | sIL2ra >2132 ngA serum IL6, sTNFrl, or neopterin levels and QoL scores were not detected.
Immune products, QoL and survival
Stepwise multiple regression analysis including survival, pretreatment tumour volume, and pretreatment serum alkaline phosphatase, CEA and immune product levels as independent variables, selected sIL2ra as a significant independent predictor (Table 2 ) of HAD scale depression score.
DISCUSSION
Serum sIL2ra concentrations were associated with increased HAD scale depression scores independently of more conventional clinical variables such as tumour volume or serum alkaline phosphatase and CEA ( Table 2 ). The correlations between serum immune product levels and liver metastasis volume before chemotherapy suggest that the immune product increases were disease-related. Thus tumour-related immune products could be the 'toxins' previously proposed to explain QoL differences unexplained by variations in liver metastasis volume1. The source of the circulating immune products was not identified in this study, but was probably T lymphocytes20 and macrophages2l that had been stimulated by tumourassociated antigens22. The finding that patients with high pretreatment sIL2rac levels had greater tumour volume and lower survival seems inconsistent with studies suggesting that T-lymphocyte IL2 production23 and cell-mediated immunity24 is most impaired in advanced colorectal cancer. However, previous reports of greater sIL2rcx increases in patients with advanced than in early colorectal25'26, gastric27 and ovarian28 carcinoma are in accord with our findings. Animal studies have suggested that T-lymphocyte 'anergy' may arise where there is incomplete T-cell binding to the antigen presenting cell29, resulting in 'stage 1' (IL2 receptor) but not 'stage 2'
(lymphocyte proliferation and cytokine production) activation. Incomplete T-lymphocyte activation could explain our findings of increased serum sIL2ra levels in those patients who are most anergic and have the most advanced tumours.
Survival was lower in patients with raised pretreatment serum sIL2ra, sTNFrl and IL6 levels than in those with normal results. However, serum sIL2ra was the only statistically significant independent survival predictor (Table  1) found in this study, and in addition to survival, QoL decreases with disease progression'. Thus one explanation for the relation between serum sIL2ra, depression and survival might be that circulating immune products were tumour-related epiphenomena that reflected the survivallimiting effects of the tumour, and thereby provided information about survival-related depression. However, the finding that survival was not selected as a predictor of HAD scale depression or any other QoL score when it was included as an independent variable in regression analyses ( Table 2 ) did not support the view that the relation of sIL2roc with QoL could be fully explained by sIL2ra being a survival-dependent variable. The findings were more consistent with serum sIL2ra independently predicting both HAD scale depression score ( Table 2 ) and survival (Table 1) . The mechanism for the association between depression and sL2rac is not clear. Although sL2rac was the strongest QoL-related factor identified, this study could not establish which components of the immune response might influence quality of life. Cytokines have overlapping functions and act synergistically so that small alterations in particular combinations of cytokines can have large effects. They are capable of a wide array of direct interactions-for example, with central nervous system4,30, liver, and muscle receptors31-and are thought to mediate wasting in cancer32. Our results were consistent with tumour-initiated circulating products of immune activation interacting with distant receptors to produce depression.
Treatment-related quality of life differences between systemic and hepatic arterial chemotherapies have been reported33, and immune activation might vary with chemotherapy and toxicity. However, serum immune product levels were measured before chemotherapy in this study, and the finding that they correlated with tumour volume did not suggest that their elevation could be attributed to chemotherapy. Since a survival difference between systemic and regional chemotherapies for colorectal liver metastases has not been demonstrated34, this is unlikely to have biased correlations between survival and immune products. The absence of a difference in prechemotherapy serum immune product levels between systemic and hepatic artery chemotherapy patients does not suggest that the laparotomy which was required for hepatic arterial cannulation35 affected serum immune product levels in the study patients.
Although these findings support the hypothesis that tumour-induced immune activation contributes to depression in cancer, correlation does not establish cause and effect. Further studies are required to evaluate these preliminary results in more detail.
